SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017
October 05, 2017 08:30 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Oct. 05, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often...
SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017
September 27, 2017 08:30 ET
|
SCYNEXIS, Inc.
Additional SCY-078 Posters to be Presented at 8th Trends in Medical Mycology Pre-clinical data further highlight SCY-078’s broad spectrum of activity and differentiated attributes JERSEY CITY, N.J.,...
SCYNEXIS to Present at Upcoming Investor Conferences
August 31, 2017 09:05 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Aug. 31, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often...
“THINK FUNGUS” - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention (CDC)
August 15, 2017 08:00 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Aug. 15, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often...
SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting
August 14, 2017 08:00 ET
|
SCYNEXIS, Inc.
Potent anti-Candida activity shown in vaginal acidic pH and high penetration into vaginal tissue Positive efficacy data reported from proof-of-concept Phase 2 VVC study JERSEY CITY, N.J., Aug. 14,...
SCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update
August 08, 2017 16:25 ET
|
SCYNEXIS, Inc.
Dosing Initiated in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis Recent Data Publications Showcase Broad and Potent Activity of SCY-078 Against Multiple Fungal Species...
SCYNEXIS to Present at the Canaccord Genuity Growth Conference
August 07, 2017 09:05 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often...
SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis
August 03, 2017 16:05 ET
|
SCYNEXIS, Inc.
Study initiation marks important milestone following promising clinical results in previous Phase 2 study Additional pre-clinical results for VVC to be presented at upcoming 2017 IDSOG Annual Meeting...
New Study Further Demonstrates In Vitro Activity of SCYNEXIS’ Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains
June 15, 2017 08:30 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., June 15, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often...
SCYNEXIS, Inc. to Participate in the 2017 BIO International Convention
June 13, 2017 09:05 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., June 13, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often...